The autoantibody to GNAS can distinguish more HCC patients with early-stage (43.4% and 62.4%) than HCC patients with late-stage (32.6% and 51.5%) in discovery and validation phases, respectively. Here, GNAS is linked to hepatocellular carcinoma.